A detailed history of Russell Investments Group, Ltd. transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 190,196 shares of RVMD stock, worth $9.45 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
190,196
Previous 276,230 31.15%
Holding current value
$9.45 Million
Previous $9.77 Million 28.36%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025

SELL
$31.13 - $41.98 $2.68 Million - $3.61 Million
-86,034 Reduced 31.15%
190,196 $7 Million
Q1 2025

May 13, 2025

BUY
$35.36 - $44.42 $9.62 Million - $12.1 Million
271,987 Added 6410.25%
276,230 $9.77 Million
Q4 2024

Feb 13, 2025

BUY
$42.97 - $60.6 $18,648 - $26,300
434 Added 11.39%
4,243 $185,000
Q3 2024

Nov 13, 2024

SELL
$36.92 - $47.94 $82,442 - $107,050
-2,233 Reduced 36.96%
3,809 $172,000
Q2 2024

Aug 08, 2024

BUY
$30.14 - $40.68 $171,617 - $231,631
5,694 Added 1636.21%
6,042 $234,000
Q4 2023

Feb 05, 2024

BUY
$18.35 - $34.12 $146 - $272
8 Added 2.35%
348 $9,000
Q1 2023

May 09, 2023

BUY
$20.76 - $30.09 $7,058 - $10,230
340 New
340 $7,000
Q3 2021

Nov 08, 2021

SELL
$23.95 - $33.41 $202,664 - $282,715
-8,462 Closed
0 $0
Q2 2021

Aug 04, 2021

SELL
$29.0 - $47.44 $693,622 - $1.13 Million
-23,918 Reduced 73.87%
8,462 $268,000
Q1 2021

May 10, 2021

SELL
$37.21 - $54.43 $614,671 - $899,129
-16,519 Reduced 33.78%
32,380 $1.49 Million
Q4 2020

Feb 08, 2021

BUY
$30.19 - $45.49 $1.22 Million - $1.84 Million
40,437 Added 477.87%
48,899 $1.94 Million
Q3 2020

Nov 09, 2020

BUY
$22.61 - $34.8 $191,325 - $294,477
8,462 New
8,462 $294,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $4.36B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.